Value through Innovation27 July 2016

Clinical Study Results

  • BUSCOPAN ® - Abdominal Pain
    Clinical Study Number 202.838
    Study Indication Abdominal Pain
    Product BUSCOPAN ®
    Generic Name Hyoscine butylbromide
    Lab Code
    Clinical Phase IIIb
    Study Title

    A randomized, double-blind, double-dummy, active-controlled, parallel-group, multicentertrial, in contrast with Hyoscine Butylbromide Capsule 10mg , to evaluate the efficacy and safety of Hyoscine Butylbromide tablets 10 mg (20mg, 3 times daily, orally) over a period of 3 days for the treatment of occasional or recurrent episodes of selfreported gastric or intestinal spasm-like pain

    Study Document Trial synopsis 202.838_CO english
  • BUSCOPAN ® - Abdominal Pain
    Clinical Study Number 202.839
    Study Indication Abdominal Pain
    Product BUSCOPAN ®
    Generic Name Hyoscine butylbromide
    Lab Code
    Clinical Phase II
    Study Title

    A double-blind, placebo controlled, randomized, parallel group study of the efficacy and tolerability of oral doses of 20 mg hyoscine butylbromide when used on demand for the treatment of self reported functional abdominal pain or discomfort associated with cramping

    Study Document Trial synopsis 202.839_CO english
  • BUSCOPAN® PLUS - Abdominal Pain
    Clinical Study Number 218.705
    Study Indication Abdominal Pain
    Product BUSCOPAN® PLUS
    Generic Name Hyoscine butylbromide + Paracetamol
    Lab Code
    Clinical Phase IV
    Study Title

    Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima

    Study Document Trial synopsis 218.705 english
  • BI 1026706 - Abdominal Pain
    Clinical Study Number 1320.22
    Study Indication Abdominal Pain
    Product BI 1026706
    Generic Name BI 1026706
    Lab Code BI 1026706
    Clinical Phase IIa
    Study Title

    A randomised, double-masked, placebo-controlled exploratory study to evaluate pharmacodynamics, safety, and tolerability of orally administered BI 1026706 for 12 weeks in patients with mild visual impairment due to centre-involved diabetic macular oedema (DME)

    Study Document Trial synopsis 1320.22 english Lay summary 1320.22 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.